TY - JOUR
T1 - Liver Fat Is Associated With Markers of Inflammation and Oxidative Stress in Analysis of Data From the Framingham Heart Study
AU - Fricker, Zachary P.
AU - Pedley, Alison
AU - Massaro, Joseph M.
AU - Vasan, Ramachandran S.
AU - Hoffmann, Udo
AU - Benjamin, Emelia J.
AU - Long, Michelle T.
N1 - Funding Information:
Funding Supported in part by the Boston University Clinical and Translational Science Institute (UL1-TR000157) (Z.P.F.); the Evans Medical Foundation and the Jay and Louis Coffman Endowment (R.S.V.); National Institutes of Health grants 1R01HL128914, 2R01 HL092577, 1RO1 HL64753, R01 HL076784, and 1 R01 AG028321 (E.J.B.); and National Institutes of Health grant K23 DK113252, the Boston University School of Medicine Department of Medicine Career Investment Award, and the Boston University Clinical Translational Science Institute UL1 TR001430 (M.T.L.). Also supported by the Boston University School of Medicine and the National Heart, Lung, and Blood Institute's contract N01-HC-25195 and HHSN268201500001I, R01 HL 71039, and K24 HL 4334 (R.S.V.), and the Division of Intramural Research of the National Heart, Lung, and Blood Institute, Bethesda, MD.
Publisher Copyright:
© 2019 AGA Institute
PY - 2019/5
Y1 - 2019/5
N2 - Background & Aims: Nonalcoholic fatty liver disease is an inflammatory condition that results in progressive liver disease. It is unknown if individuals with hepatic steatosis, but not known to have liver disease, have higher serum concentrations of markers of systemic inflammation and oxidative stress. Methods: We collected data from 2482 participants from the Framingham Heart Study (mean age, 51 ± 11 y; 51% women) who underwent computed tomography and measurement of 14 serum markers of systemic inflammation. Heavy alcohol users were excluded. The liver:phantom ratio (a continuous parameter of liver attenuation relative to a calibration phantom) was used to identify individuals with radiographic evidence of liver fat. Primary covariates included age, sex, smoking, alcohol, aspirin use, hypertension, dyslipidemia, diabetes, and cardiovascular disease. Body mass index and visceral fat were secondary covariates. We used multivariable linear regression models to assess the association between liver fat and systemic inflammatory markers. Results: In multivariable-adjusted models, liver fat was associated with the following inflammatory markers: high-sensitivity C-reactive protein (P <.001), urinary isoprostanes (P <.001), interleukin 6 (P <.001), intercellular adhesion molecule 1 (P <.001), and P-selectin (P =.002). Additional adjustment for body mass index or visceral fat attenuated the results slightly, although all associations remained statistically significant (P for all ≤.01). Conclusions: In a community-based cohort, individuals with hepatic steatosis without known liver disease had higher mean serum concentrations of systemic markers of inflammation. Studies are needed to determine whether treatment of hepatic steatosis reduces systemic inflammation.
AB - Background & Aims: Nonalcoholic fatty liver disease is an inflammatory condition that results in progressive liver disease. It is unknown if individuals with hepatic steatosis, but not known to have liver disease, have higher serum concentrations of markers of systemic inflammation and oxidative stress. Methods: We collected data from 2482 participants from the Framingham Heart Study (mean age, 51 ± 11 y; 51% women) who underwent computed tomography and measurement of 14 serum markers of systemic inflammation. Heavy alcohol users were excluded. The liver:phantom ratio (a continuous parameter of liver attenuation relative to a calibration phantom) was used to identify individuals with radiographic evidence of liver fat. Primary covariates included age, sex, smoking, alcohol, aspirin use, hypertension, dyslipidemia, diabetes, and cardiovascular disease. Body mass index and visceral fat were secondary covariates. We used multivariable linear regression models to assess the association between liver fat and systemic inflammatory markers. Results: In multivariable-adjusted models, liver fat was associated with the following inflammatory markers: high-sensitivity C-reactive protein (P <.001), urinary isoprostanes (P <.001), interleukin 6 (P <.001), intercellular adhesion molecule 1 (P <.001), and P-selectin (P =.002). Additional adjustment for body mass index or visceral fat attenuated the results slightly, although all associations remained statistically significant (P for all ≤.01). Conclusions: In a community-based cohort, individuals with hepatic steatosis without known liver disease had higher mean serum concentrations of systemic markers of inflammation. Studies are needed to determine whether treatment of hepatic steatosis reduces systemic inflammation.
KW - Bomarkers
KW - Cardiovascular Disease
KW - NAFLD
KW - Steatosis
UR - http://www.scopus.com/inward/record.url?scp=85064322726&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064322726&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2018.11.037
DO - 10.1016/j.cgh.2018.11.037
M3 - Article
C2 - 30476583
AN - SCOPUS:85064322726
VL - 17
SP - 1157-1164.e4
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
SN - 1542-3565
IS - 6
ER -